Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Randomized Controlled Trial to Evaluate the Effect of White Noises and Parental Voices as Protectors Against Noise Damage in a Neonatal Intensive Care Unit

12 de noviembre de 2026 actualizado por: Istituto Giannina Gaslini

La voz de los padres y los ruidos blancos en la unidad de cuidados intensivos neonatales: evaluación de la eficacia contra el daño de los ruidos: un ensayo controlado aleatorio

The goal of this Randomized Controlled Trial is to test the efficacy of listening to white noises and parental voices against environmental noise damage in premature babies admitted to the Newborn Intensive Care Unit.

The main question it aims to answer is:

• Could the combined use of white noises and maternal and/or paternal voices reduce the negative outcomes of continuous exposure to hospital noises on newborns hospitalized in a Neonatal Intensive Care Unit?

Participants in the intervention group will listen to a recorded track composed of white noises and voices of their parents who read a story or sing a lullaby from the day of enrollment until the day of discharge, for 4 hours per day.

Researchers will compare the intervention group with the control group (who will receive the usual care provided without any intervention on the noise level) to see if babies enrolled in the intervention group show fewer events of tachycardia, tachypnea, desaturation, apnoea, and language or hearing impairment.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

11

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Genova
      • Genova, Genova, Italia, 16145
        • IRCCS Istituto Giannina Gaslini

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

7 meses y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients admitted to the NICU with gestational age at birth ≥ 31 weeks (as this is the age at which sound perception is ≥ 40 dB and there is predictable clinical stability to allow intervention delivery without excessive interruptions)
  • Patients admitted to the NICU who reach gestational age ≥ 31 weeks
  • Patients monitored with the following types of monitors: Masimo rainbow SET™ (Masimo); Infinity® Delta (Draeger); Infinity® Acute Care System (Draeger); Efficia CM (Philips).

Exclusion Criteria:

  • Patients with gestational age at birth < 31 weeks
  • Patients affected by meningitis or severe cerebral insults, congenital brain anomalies, congenital syndromes with suspected or known brain dysfunction
  • Patients diagnosed with hypoxic-ischemic encephalopathy
  • Patients with significant airway abnormalities resulting in altered breathing during sleep
  • Patients with terminal illnesses
  • Patients with congenital anomalies of the face, ears, skull, or brain
  • Patients with non-bacterial congenital infections
  • Patients with congenital hearing deficits
  • Patients whose parents or legal guardians refuse to participate in the study
  • Patients already enrolled in other clinical studies.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intervention Group

Those in the intervention group will receive the administration of white noises and maternal and/or paternal voice recording.

The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.

The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.

The volume will be 45 dB for infants in incubators and infants in open cribs.

Sin intervención: Control Group

Those enrolled in the control group will receive standard care and will be subjected to the usual level of ambient noise.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Reduction of heart rate alteration
Periodo de tiempo: Through study completion, an average of 2 year

Reduction, in the patients enrolled in the intervention group compared to the control group, in episodes of heart rate alteration associated with noises > 45 dB (nursing diagnosis: risk of tachycardia - HR >180 bpm - correlated with environmental exposure to noises > 45dB).

Through study completion, an average of 2 year
Reduction of oxygen saturation alteration
Periodo de tiempo: Through study completion, an average of 2 year

Reduction, in the patients enrolled in the intervention group compared to the control group, in episodes of oxygen saturation alteration associated with noises > 45 dB (nursing diagnosis: risk of desaturation - SpO2 <90% - correlated with environmental exposure to noises > 45dB).

Through study completion, an average of 2 year
Reduction of respiratory rate alteration
Periodo de tiempo: Through study completion, an average of 2 year

Reduction, in the patients enrolled in the intervention group compared to the control group, in episodes of respiratory rate alteration associated with noises > 45 dB (nursing diagnosis: risk of tachypnoea - RR >60 breaths per minute - correlated with environmental exposure to noises > 45dB).

Through study completion, an average of 2 year
Reduction of episodes of apnoea
Periodo de tiempo: Through study completion, an average of 2 year

Reduction, in the patients enrolled in the intervention group compared to the control group, in episodes of apnoea associated with noises > 45 dB (nursing diagnosis: risk of apnoea - HR <100 bpm and SpO2 <90% - correlated with environmental exposure to noises > 45dB).

Through study completion, an average of 2 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Reduction in Language Development Alterations
Periodo de tiempo: From enrollment unitl 3 years of age

The study will assess whether there is a reduction in language development issues in the intervention group compared to the control group. This evaluation will be conducted during a follow-up assessment at 3 years of age. The nursing diagnosis being considered is "risk of impaired verbal communication related to hospitalization in the NICU."

From enrollment unitl 3 years of age
Reduction in Hearing Development Alterations
Periodo de tiempo: From enrollment unitl 3 months of age

The study will also assess whether there is a reduction in hearing development issues in the intervention group compared to the control group. These evaluations will be conducted at a follow-up assessment at 3 months of age and any subsequent audiometric examinations. The nursing diagnosis being considered is "risk of compromised hearing development related to hospitalization in the NICU."

From enrollment unitl 3 months of age

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Silla de estudio: Simona Serveli, RN, Department of Health Profession, IRCCS Istituto Giannina Gaslini

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de febrero de 2024

Finalización primaria (Actual)

31 de diciembre de 2024

Finalización del estudio (Actual)

31 de diciembre de 2024

Fechas de registro del estudio

Enviado por primera vez

13 de noviembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

20 de noviembre de 2023

Publicado por primera vez (Actual)

29 de noviembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data could be shared under a motivated request, only anonymised and grouped in databases.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir